Matthews W B, Oxbury J M, Grainger K M, Greenhall R C
Brain. 1976 Jun;99(2):193-206. doi: 10.1093/brain/99.2.193.
A blind controlled trial of dextran 40 in ischaemic stroke is reported. In the treated group mortality in the acute stage in patients with severe strokes was significantly reduced but survivors were severely disabled and six months later no significant benefit could be detected. In less severe strokes no effect of treatment was found. It is concluded that the action of dextran 40 in reducing acute mortality probably lay in preventing or reversing cerebral swelling but no evidence of the expected action in reducing the area of infarction following improved blood flow was found. The importance of extending assessment beyond the two weeks customary in therapeutic trials in stroke is emphasized.
本文报道了右旋糖酐40治疗缺血性中风的一项双盲对照试验。在治疗组中，重症中风患者急性期的死亡率显著降低，但幸存者严重致残，6个月后未发现显著益处。在病情较轻的中风患者中，未发现治疗效果。结论是，右旋糖酐40降低急性死亡率的作用可能在于预防或逆转脑肿胀，但未发现其在改善血流后减少梗死面积方面有预期作用的证据。强调了在中风治疗试验中，将评估时间延长至超过通常的两周的重要性。
